Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona (UB) have described the ability of an inhibitor of the PI3Kα (BYL719) to block the ectopic bone formation in mice. This could lead to improve the treatment of two pathologies: heterotopic ossification and fibrodysplasia ossificans progressiva (FOP, a rare bone disease). The study was led by Dr. Francesc Ventura, head of the Cell Signaling and Bone Biology group.
from http://besthealthnews.com/2019/08/new-treatment-could-improve-care-for-two-bone-diseases/?utm_source=rss&utm_medium=rss&utm_campaign=new-treatment-could-improve-care-for-two-bone-diseases
from
https://healthnews010.tumblr.com/post/186738378453
No comments:
Post a Comment